Browsing by Author "Zachou, Kalliopi"
Now showing items 1-6 of 6
-
Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome
Keskin, Onur; Wedemeyer, Heiner; Tuzun, Ali; Zachou, Kalliopi; Deda, Xheni; Dalekos, George N.; Heidrich, Benjamin (Elsevier Science Inc, 2015)BACKGROUND & AIMS: Interferon is the only effective treatment for chronic hepatitis D virus (HDV) infection. No rules have been set for stopping treatment based on viral kinetics. We analyzed data from an international ... -
BASELINE ALT LEVELS BUT NOT HDV-RNA LEVELS ARE ASSOCIATED WITH RESPONSE TO PEGYLATED INTERFERON ALFA-2A TREATMENT OF DELTA HEPATITIS: DATA FROM THE HIDIT-1 TRIAL
Wedemeyer, Heiner; Yurdaydin, Cihan; Zachou, Kalliopi; Erhardi, Annette; Cakaloglu, Yilmaz; Yalcin, Kendal; Gurel, Selim (John Wiley & Sons Inc, 2008)[Abstract Not Available] -
Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta
Heidrich, Benjamin; Yurdaydın, Cihan; Kabacam, Gökhan; Ratsch, Boris A.; Zachou, Kalliopi; Bremer, Birgit; Dalekos, George N.; Yalçın, Kendal (Wiley, 2014)Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity rates of 25-30% 24 weeks after therapy. ... -
Pegylated interferon-alfa-2A plus adefovir combination therapy is superior to pegylated interferon-alfa-2A alone or adefovir monotherapy in reducing HBsAg levels in hdvcoinfected patients with low HBV viremia
Wedemeyer, Heiner; Yurdaydin, Cihan; Zachou, Kalliopi; Erhardt, Alexander; Drebber, Ulrike; Cakaloglu, Ya; Degertekin, Ha (John Wiley & Sons Inc, 2006)[Abstract Not Available] -
Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis
Kabacam, Gokhan; Dalekos, George N.; Cakaloglu, Yilmaz; Zachou, Kalliopi; Bock, Thomas; Erhardt, Andreas; Zeuzem, Stefan (Aves, 2012)Background/aims: The safety and efficacy of interferons in advanced delta hepatitis have not been explored. The aim of this subanalysis of a multi-center clinical trial was to compare the efficacy and safety of 48 weeks ... -
Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis
Zachou, Kalliopi; Yurdaydin, Cihan; Drebber, Uta; Dalekos, George N.; Erhardt, Andreas; Cakaloglu, Yilmaz; Degertekin, Halil (Wiley, 2010)Background: Hepatitis delta virus (HDV) causes severe liver disease. Aims: To investigate the quantitative HDV-RNA, HBsAg and hepatitis B virus (HBV)DNA levels in correlation to histological, biochemical and demographical ...